Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Aigen Investment Management LP

Aigen Investment Management LP lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 35.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 8,942 shares of the biopharmaceutical company’s stock after acquiring an additional 2,361 shares during the quarter. Aigen Investment Management LP’s holdings in Halozyme Therapeutics were worth $330,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in HALO. Principal Securities Inc. bought a new position in Halozyme Therapeutics in the fourth quarter worth about $34,000. First Horizon Advisors Inc. increased its position in Halozyme Therapeutics by 24.5% in the fourth quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 293 shares during the period. Parkside Financial Bank & Trust acquired a new position in shares of Halozyme Therapeutics during the fourth quarter valued at $64,000. Headlands Technologies LLC increased its holdings in shares of Halozyme Therapeutics by 1,068.2% in the 4th quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 1,613 shares during the period. Finally, Quadrant Capital Group LLC grew its position in Halozyme Therapeutics by 22.4% in the 4th quarter. Quadrant Capital Group LLC now owns 3,414 shares of the biopharmaceutical company’s stock worth $126,000 after purchasing an additional 624 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total value of $416,400.00. Following the transaction, the senior vice president now owns 156,558 shares in the company, valued at approximately $6,519,075.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In the last ninety days, insiders sold 40,000 shares of company stock worth $1,650,600. 2.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on HALO shares. JMP Securities reduced their price objective on Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 8th. Benchmark reiterated a “buy” rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a research report on Tuesday, April 16th. StockNews.com upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, February 23rd. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday. Finally, TD Cowen started coverage on Halozyme Therapeutics in a research report on Thursday, February 29th. They issued an “outperform” rating and a $54.00 target price for the company. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $53.14.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO traded down $0.10 during trading on Friday, hitting $43.82. The company had a trading volume of 898,705 shares, compared to its average volume of 1,041,106. The company has a market cap of $5.58 billion, a P/E ratio of 18.11, a PEG ratio of 0.49 and a beta of 1.26. The company has a debt-to-equity ratio of 8.44, a quick ratio of 5.36 and a current ratio of 6.64. The business’s 50-day moving average is $40.88 and its 200 day moving average is $38.84. Halozyme Therapeutics, Inc. has a 52 week low of $31.86 and a 52 week high of $46.16.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The firm had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 3.44 earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.